Welcome to our dedicated page for SENZIME AB ORD news (Ticker: $snzzf), a resource for investors and traders seeking the latest updates and insights on SENZIME AB ORD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SENZIME AB ORD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SENZIME AB ORD's position in the market.
Senzime AB reported a 66% increase in net sales for January - March 2024, with sales of instruments up by 41% and disposables up by 89%. The gross margin decreased to 64.3%, EBITDA improved, but profit after financial items showed a loss. Cash and cash equivalents increased to TSEK 116,856. The company secured a significant deal in the US and saw growth in Japan and South Korea. CEO Philip Siberg highlighted the strong sales growth and emphasized the focus on building a market-leading position. The future outlook remains optimistic with high demand in the market.
Senzime invites investors, analysts, and media to a webcast presentation of the first quarter report for 2024 on May 7th. The presentation will be held by Philip Siberg, CEO, with a Q&A session moderated by an analyst from Carnegie Investment Bank. The event will be held in English and can be accessed via webcast.
